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Abstract
Introduction: Two cases of impotence following a treatment with etretinate have been reported
in the literature. Acitretin is the principal active metabolite of etretinate. We report a case of
erectile dysfunction associated with the use of acitretin.
Case presentation: A 39-year-old Caucasian man referred his incapacity to reach and maintain
a penile erection during a course of acitretin for the treatment of a severe form of psoriasis.
Physical examination, laboratory findings and psychological analysis did not reveal any
abnormalities. Two weeks after the withdrawal of acitretin, the patient reported a normalization
of his sexual activity.
Conclusion:  Retinoids have been associated with male reproductive system dysfunctions in
human and animal studies. Clinicians should be aware of the possibility of acitretin-induced erectile
dysfunction.
Introduction
Acitretin is a synthetic aromatic retinoid used to treat der-
matologic diseases, especially psoriasis and related skin
disorders. The major adverse effects observed with retin-
oids treatment have been essentially embryotoxicity, tera-
togenicity, mucocutaneous reactions, pruritus,
hypertriglyceridemia, hypercholesterolemia, increases in
liver transaminase concentrations and bone abnormali-
ties. Acitretin is the principal active metabolite of etreti-
nate, formerly approved for psoriasis, but withdrawn
from the market because of its undesirable pharmacoki-
netic profile. We report a case of erectile dysfunction fol-
lowing a treatment with acitretin.
Case presentation
A 39-year-old Caucasian man affected by psoriasis from
approximately two years presented to our outpatient
department with a worsening of his psoriatic lesions pre-
viously controlled by topical steroids and ultra-violet ther-
apy.
The patient had no history of tobacco or alcohol use and
he had not undergone major surgery. He was not taking
drugs and his routine blood tests, hepatitis markers, coag-
ulation parameters, thyroid function and chest radiogra-
phy were normal.
After histological examinations, he started a treatment
with acitretin 25 mg/die. His psoriatic plaques resolved
after two months and the dose was reduced to 20 mg/die.
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In a follow-up visit the patient reported his incapacity to
reach and maintain a penile erection sufficient to perform
a sexual act from approximately 45 days. The patient also
referred the absence of morning erections. Physical exam-
ination of the external genital organs revealed neither
fibromatous plaques, nor signs of vascular, endocrine or
neurological diseases. Laboratory findings did not show
any alterations and clinical symptoms of depression were
not present.
We hypothesized a role of acitretin in the genesis of the
erectile dysfunction, thus we decided to withdraw the
drug with the consent of the patient. After two weeks he
reported a normalization of his sexual activity and
decided not to start a new course of acitretin despite the
worsening of his psoriatic lesions.
Discussion
A literature search using PubMed did not reveal any case
reports on the association between acitretin use and erec-
tile dysfunction. However, we retrieved two cases of impo-
tence related to etretinate therapy. Etretinate has been
detected in the plasma of patients receiving acitretin,
because it is readily esterified in vivo to produce etretinate,
especially in the presence of ethanol [1].
In the first case, the authors associated the erectile dys-
function with the use of etretinate in a 37-year-old patient
with symptoms of depression on the basis of a positive
dechallenge [2].
The second case, described in a 40-year-old patient with-
out symptoms of depression, was confirmed by a positive
rechallenge [3].
Acitretin has been associated to erectile dysfunction dur-
ing spontaneous surveillance. We retrieved 2 cases in the
database of the Netherlands Pharmacovigilance Centre
LAREB [4] and 6 cases in the database of the Medical and
Healthcare products Regulatory Agency of UK [5].
Other retinoids were involved in cases of erectile dysfunc-
tion. During a prospective study designed to evaluate the
efficacy and safety of isotretinoin in the treatment of acne,
six male patients referred difficulties in maintaining
penile erection in association with clinical symptoms of
depression [6]. One case of ejaculatory disorder related to
the use of isotretinoin has been reported [7]. Retinoids
activity on male reproductive system was observed in ani-
mal studies. Single neonatal treatment with retinol dra-
matically reduced the sexual activity of adult male rats [8].
In animals treated with retinoids, testicular atrophy with
spermatogenetic arrest was described [9].
Our diagnosis is based only on the anamnesis and a pos-
itive dechallenge, as the patient preferred not to contact an
urologist for his dysfunction and he did not agree to
resume the treatment with acitretin, therefore a rechal-
lenge was not possible.
On the basis of the literature review, we hypothesize a
class effect of retinoids on erectile function. According to
the animal studies [8,9], erectile dysfunction associated
with retinoids therapy could be caused by a direct action
on the male reproductive system, although a role of
depression can not be excluded [10].
Patients are reluctant to report sexual dysfunctions during
their contacts with practitioners, therefore it is likely that
the incidence of similar effects may result underestimated.
Conclusion
To our knowledge, no case of acitretin-associated impo-
tence has been published to date. The case described has
been reported to the Italian Pharmacovigilance System
and to the manufacturer of the drug.
Prescribers of the drug, particularly dermatologists,
should be aware of the possibility of such adverse reac-
tions during a treatment with acitretin.
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